Authors
Loading...
Experiments demonstrate that osivelotor and losartan enhance kidney function in sickle cell models, suggesting dual-targeting is beneficial.
Setty et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: